Speculator makes case for candidates to end years of hurt for stem cell investors

Most early stage stem cell investors have lost their shirts, admits a market commentator as it puts forward the case for investment in a handful or current biotech companies that might be worth a punt.

Microcap Speculators, which provides reports, company profiles and other investor relations materials, has published a commentary on these companies and the wider area of research, entitled The Big Deal About Stem Cell Therapies and Regenerative Medicine.

"The dot-com like era of regenerative medicine is over. Investors will need to look at companies solving issues with stem cells or those taking a completely new approach"